Navigation Links
Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
Date:5/22/2008

CAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on ou
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
7. Micromet Announces Changes in Management Team
8. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
11. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced its victory ... manufacturer BMC Medical Co., Ltd. The International ... infringe ResMed,s patents, and entered an order prohibiting BMC from ... United States : , iVolve nasal mask ... pillows mask , iVolve full face mask ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... SAN DIEGO, Oct. 7 CareFusion Corporation (NYSE: CFN ) ... 2010 on Tuesday, Nov. 10 following the close of trading on ... webcast and conference call on Nov. 10 at 2:00 pm Pacific ... first quarter, ended on Sep. 30, 2009. To access the call ...
... October 7 DBMS Consulting announced that it,has successfully ... Oracle E-Business Suite (EBS) for SIRO Clinpharm, one of ... fully,automated capabilities in management of clinical trial process, clinical,trial ... After this implementation, SIRO gains complete operational ...
Cached Medicine Technology:CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010 2DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm 2DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm 3
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping ... of the models at LunaDress.co.uk come with big discounts, up to ... veil can turn out to be a most exciting memory and ... always bring surprise to a wedding. On the updated fashion blog, ... veils for a big day . , Going out with friends ...
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... new resource - www.breastfeedinginsurance.com - where new and expectant mothers can access comprehensive information and tools to help them discover if ... ... , , ... ...
... March 11 As reported in today,s Wall ... with atrial fibrillation are now on notice that the over-zealous marketing ... not approved by the U.S. Food and Drug Administration (FDA) for ... and hospitals, decisions about treatment for their patients, heart conditions. ...
... Weakness in rotator cuff a warning sign, but exercise regimens ... -- As another baseball season nears, researchers report that preseason ... those pitchers at high risk of developing a shoulder injury ... cuff where, if they are weaker, players are more likely ...
... who had the flu while pregnant had smaller brains and ... patients with schizophrenia, a study at the University of Wisconsin-Madison ... Hill has found. The study, published online by the ... with monkeys that examines the effects of flu during pregnancy. ...
... , ... Medication and E-prescribing Company Depends on StrataScale’s Flagship Service for Reliable, Secure, Highly-scaleable ... ... fully automated managed hosting solution, today announced that Dr. Dispense, a point of ...
... ... ... VCAD is inviting the public to an evening presentation of fashion and costume history on ... 20th Century," covering the changing trends and styles of fashion from the 1890s through to ...
Cached Medicine News:Health News:Medela Announces Launch of New Insurance Reimbursement Resource for New and Expectant Mothers 2Health News:Medela Announces Launch of New Insurance Reimbursement Resource for New and Expectant Mothers 3Health News:Medela Announces Launch of New Insurance Reimbursement Resource for New and Expectant Mothers 4Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 2Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 3Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 4Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 5Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 6Health News:Pre-Season Test Spots Baseball Pitchers at Risk of Injury 2Health News:Pre-Season Test Spots Baseball Pitchers at Risk of Injury 3Health News:Mother's flu during pregnancy may increase baby's risk of schizophrenia 2Health News:Dr. Dispense Chooses World's First Fully Automated Managed Hosting Solution from StrataScale for All Outsourcing Needs 2Health News:Dr. Dispense Chooses World's First Fully Automated Managed Hosting Solution from StrataScale for All Outsourcing Needs 3Health News:Go Beyond Retro to Discover the World of 20th Century Fashion! 2
... has the right product for any patient ... intubated patients to patients with tracheotomies. These ... and critical care applications., ,The Unti-Mist ... patients and staff members. This entire product ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... Since 1991 Intersurgical Incorporated ... filters, heat and moisture ... therapy products, hand-held nebulizers ... of accessories and connectors ...
... Ulti-Mist™ HME product line has the right ... to adults and from intubated patients to ... humidification for both anesthesia and critical care ... provide maximum protection for patients and staff ...
Medicine Products: